Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • EHA 2025

European Hematology Association - 30th Congress Milan Italy

June 12 - 17, 2025

  1. All
  2. HSCT-TMA 
  3. PNH

PDF

Exposure response of ravulizumab to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy

PDF

Ravulizumab plus best supportive care to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy: first results from a phase 3 trial

HTML

Assessment of long-term renal function in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab in a phase 3 open-label study

HTML

A real-world, multi-center, prospective, observational study for paroxysmal nocturnal hemoglobinuria (PNH) in China: preliminary results

PDF

Both rare PNH cells and minor PNH clones should be considered as genuine PNH clones: insights from analysis of the 5-year French nation-wide multicenter observational study

PDF

Danicopan add-on to ravulizumab or eculizumab in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis stratified by bone marrow failure history

PDF

High proportion of PNH type II neutrophils, i.e relative percentage ≥3%, Is associated with thrombosis in patients displaying a PNH clone >1%: evidence from analysis of the 5-Year french nation-wide Multicenter observational study

HTML

Real-world effectiveness of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: The US POLESTAR chart review study

PDF

Sustained long-term control of terminal complement activity with ravulizumab or danicopan add-on to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria

PDF

Exposure response of ravulizumab to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy

PDF

Ravulizumab plus best supportive care to treat pediatric patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy: first results from a phase 3 trial

HTML

Assessment of long-term renal function in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab in a phase 3 open-label study

HTML

A real-world, multi-center, prospective, observational study for paroxysmal nocturnal hemoglobinuria (PNH) in China: preliminary results

PDF

Both rare PNH cells and minor PNH clones should be considered as genuine PNH clones: insights from analysis of the 5-year French nation-wide multicenter observational study

PDF

Danicopan add-on to ravulizumab or eculizumab in patients with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis stratified by bone marrow failure history

PDF

High proportion of PNH type II neutrophils, i.e relative percentage ≥3%, Is associated with thrombosis in patients displaying a PNH clone >1%: evidence from analysis of the 5-Year french nation-wide Multicenter observational study

HTML

Real-world effectiveness of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: The US POLESTAR chart review study

PDF

Sustained long-term control of terminal complement activity with ravulizumab or danicopan add-on to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States